TG THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.19 USD | -1.40% |
|
+20.19% | -5.21% |
| May. 01 | Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts | MT |
| May. 01 | Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,089 | 6,703 | 2,488 | 1,584 | 2,416 | 2,346 | - | - |
| Enterprise Value (EV) 1 | 1,089 | 6,179 | 2,257 | 1,494 | 2,299 | 2,311 | 2,218 | 2,072 |
| P/E ratio | -5.66 x | -21.5 x | -7.22 x | -8.1 x | 190 x | 205 x | 25 x | 13.8 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 7,164 x | 44,097 x | 372 x | 569 x | 10.3 x | 7.6 x | 4.97 x | 3.8 x |
| EV / Revenue | 7,164 x | 40,652 x | 337 x | 536 x | 9.84 x | 7.49 x | 4.7 x | 3.36 x |
| EV / EBITDA | - | - | -6.55 x | -7.76 x | 110 x | 79.2 x | 22.9 x | 13 x |
| EV / FCF | -8.13 x | -28.8 x | -7.62 x | -8.48 x | -73.2 x | -35 x | 19.3 x | 9.11 x |
| FCF Yield | -12.3% | -3.48% | -13.1% | -11.8% | -1.37% | -2.85% | 5.19% | 11% |
| Price to Book | - | 14.1 x | 11.5 x | 27.3 x | 15.8 x | 12.4 x | 10.4 x | 5.22 x |
| Nbr of stocks (in thousands) | 98,104 | 128,848 | 130,950 | 133,915 | 141,455 | 144,904 | - | - |
| Reference price 2 | 11.10 | 52.02 | 19.00 | 11.83 | 17.08 | 16.19 | 16.19 | 16.19 |
| Announcement Date | 3/2/20 | 3/1/21 | 3/1/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.152 | 0.152 | 6.689 | 2.785 | 233.7 | 308.7 | 472.4 | 616.7 |
| EBITDA 1 | - | - | -344.5 | -192.5 | 20.84 | 29.19 | 96.75 | 159.2 |
| EBIT 1 | -169.1 | -273.6 | -344.8 | -192.8 | 20.63 | 15.81 | 104.3 | 184.1 |
| Operating Margin | -111,220.39% | -179,996.05% | -5,154.28% | -6,924.2% | 8.83% | 5.12% | 22.09% | 29.86% |
| Earnings before Tax (EBT) 1 | -172.9 | -279.4 | -348.1 | -198.3 | 13.06 | -5.659 | 104.2 | 210 |
| Net income 1 | -172.9 | -279.4 | -348.1 | -198.3 | 12.67 | 12.02 | 101.1 | 190.6 |
| Net margin | -113,730.92% | -183,803.29% | -5,204.08% | -7,121.54% | 5.42% | 3.89% | 21.41% | 30.91% |
| EPS 2 | -1.960 | -2.420 | -2.630 | -1.460 | 0.0900 | 0.0790 | 0.6470 | 1.175 |
| Free Cash Flow 1 | -133.9 | -214.9 | -296 | -176.2 | -31.41 | -65.97 | 115.1 | 227.4 |
| FCF margin | -88,097.37% | -141,357.89% | -4,425.7% | -6,326.18% | -13.44% | -21.37% | 24.37% | 36.88% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 118.97% | 142.88% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 113.8% | 119.33% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 3/1/21 | 3/1/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.03 | 2.321 | 2.016 | 0.594 | 0.094 | 0.08 | 7.803 | 16.07 | 165.8 | 43.97 | 63.47 | 65.89 | 77.98 | 89.67 | 88.57 |
| EBITDA 1 | -85.05 | -92.87 | -66.8 | -38.86 | - | -51.99 | -36.92 | -44.64 | 114.9 | -12.45 | - | -3 | 5 | 13 | - |
| EBIT 1 | -85.13 | -92.95 | -66.87 | -38.94 | -34.96 | -52.06 | -36.99 | -44.67 | 114.8 | -12.48 | -9.27 | -5.812 | -0.7156 | 13.2 | -1.134 |
| Operating Margin | -4,193.5% | -4,004.61% | -3,317.06% | -6,555.72% | -37,194.68% | -65,077.5% | -474.07% | -277.93% | 69.22% | -28.39% | -14.6% | -8.82% | -0.92% | 14.72% | -1.28% |
| Earnings before Tax (EBT) 1 | -85.64 | -93.34 | -69.01 | -40.51 | -35.82 | -52.99 | -39.23 | -47.61 | 113.9 | -14.03 | -10.68 | -7.385 | 1.004 | 12.31 | 18.91 |
| Net income 1 | -85.64 | -93.34 | -69.01 | -40.51 | -35.82 | -52.99 | -39.23 | -47.61 | 113.9 | -14.42 | -10.71 | -7.385 | -4.347 | 11.8 | 18.16 |
| Net margin | -4,218.57% | -4,021.46% | -3,423.26% | -6,819.87% | -38,104.26% | -66,242.5% | -502.78% | -296.19% | 68.71% | -32.79% | -16.87% | -11.21% | -5.57% | 13.16% | 20.5% |
| EPS 2 | -0.6500 | -0.7000 | -0.5100 | -0.3000 | -0.2600 | -0.3900 | -0.2800 | -0.3400 | 0.7300 | -0.1000 | -0.0700 | -0.0519 | -0.0276 | 0.0725 | 0.1200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/1/22 | 5/10/22 | 8/8/22 | 11/9/22 | 2/28/23 | 5/1/23 | 8/1/23 | 11/1/23 | 2/28/24 | 5/1/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 524 | 231 | 90.5 | 117 | 34.9 | 128 | 274 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -134 | -215 | -296 | -176 | -31.4 | -66 | 115 | 227 |
| ROE (net income / shareholders' equity) | - | -100% | -92% | -134% | 11.6% | 15.2% | 41.7% | 52.1% |
| ROA (Net income/ Total Assets) | - | -70.8% | -69.3% | -69.2% | 4.84% | -0.6% | 21.2% | 34.1% |
| Assets 1 | - | 394.3 | 502.6 | 286.6 | 261.6 | -2,003 | 477.1 | 558.9 |
| Book Value Per Share 2 | - | 3.690 | 1.660 | 0.4300 | 1.080 | 1.310 | 1.560 | 3.100 |
| Cash Flow per Share 2 | - | - | - | -1.300 | -0.2100 | -0.1400 | 1.000 | - |
| Capex 1 | 0.13 | 0.36 | 0.4 | 0.01 | - | 15 | 26.5 | 39 |
| Capex / Sales | 86.18% | 234.87% | 5.99% | 0.5% | - | 4.86% | 5.61% | 6.32% |
| Announcement Date | 3/2/20 | 3/1/21 | 3/1/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
16.19
USD
Average target price
31.5
USD
Spread / Average Target
+94.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.21% | 2.35B | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- TGTX Stock
- Financials TG Therapeutics, Inc.
